CLINICAL_TRIALS
trial_result
· 2017-04-17
Clinical Trial Update: EXTEND (Eltrombopag Extended Dosing Study) [Phase 3]
Summary
This clinical trial update reports the completion of the Phase 3 EXTEND study of eltrombopag (Promacta) for idiopathic thrombocytopenic purpura, with results po…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Purpura, Thrombocytopaenic, Idiopathic | Phase 3 | Status: COMPLETED | Results posted: 2017-04-17